Nemonoxacin is under clinical development by TaiGen Biotechnology and currently in Phase II for Community Acquired Pneumonia. According to GlobalData, Phase II drugs for Community Acquired Pneumonia have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nemonoxacin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nemonoxacin (Taigexyn) is a non-fluorinated quinolone antibiotic. It is formulated as hard gelatin capsules for oral route of administration. Taigexyn is indicated for the treatment of community-acquired pneumonia. Taigexyn also shown activity against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant MRSA as well as quinolone-resistant Streptococcus pneumonia.
Nemonoxacin (TG-873870) is under development for the treatment of diabetic foot infections and community-acquired pneumonia. The drug candidate is administered both oral and intravenous route. The drug candidate was also under development for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.
TaiGen Biotechnology overview
TaiGen Biotechnology, a subsidiary of TaiGen Biopharmaceuticals Holdings Ltd, is a research-based pharmaceutical company that develops novel therapeutics for infectious diseases, cancer and diabetes-related complications. The company’s pipeline products include nanofloxacin, brishafo, vlarevir and TG-1000. Its nemonoxacin is a non-fluorinated quinolone antibacterial for community acquired pneumonia, diabetic foot infection and other indications. TaiGen Biotechnology has products under development for the treatment of various conditions such as solid tumors, hematological cancers and others. The company works in partnership with other research institutes, hospitals and pharmaceutical companies. It conducts research on anti-influenza drug and anti-gram negative bacteria drug. TaiGen Biotechnology is headquartered in Taipei, Taiwan.
For a complete picture of Nemonoxacin’s drug-specific PTSR and LoA scores, buy the report here.